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Abstract
Background: Platinum resistance is a major obstacle in the treatment of epithelial ovarian cancer (EOC). Activation
of the AKT pathway promotes platinum resistance while inhibition of AKT sensitizes chemoresistant cells. Patients
with BRCA mutant EOC, and thus a defect in the homologous recombination (HR) repair pathway, demonstrate
greater clinical response to platinum and olaparib therapy than patients with BRCA wild-type EOC. MK-2206, an
allosteric inhibitor of AKT phosphorylation, sensitizes a variety of cell types to various anticancer agents and is
currently undergoing phase II trials as monotherapy for platinum-resistant ovarian, fallopian tube, and peritoneal
cancer. This study examines the differential effects of AKT inhibition with cisplatin and olaparib therapy in BRCA1/2-
deficient versus wild-type EOC.
Methods: PEO1, a chemosensitive BRCA2-mutant serous ovarian adenocarcinoma, and PEO4, a reverted BRCA2-
proficient line from the same patient after the development of chemotherapeutic resistance, were primarily used
for the study. In PEO1, MK-2206 demonstrated moderate to strong synergism with cisplatin and olaparib at all
doses, while demonstrating antagonism at all doses in PEO4.
Results: Baseline phospho-AKT activity in untreated cells was upregulated in both BRCA1- and 2-deficient cell lines.
MK-2206 prevented cisplatin- and olaparib-induced AKT activation in the BRCA2-deficient PEO1 cells. We propose
that BRCA-deficient EOC cells upregulate baseline AKT activity to enhance survival in the absence of HR. Higher
AKT activity is also required to withstand cytotoxic agent-induced DNA damage, leading to strong synergism
between MK-2206 and cisplatin or olaparib therapy in BRCA-deficient cells.
Conclusions: MK-2206 shows promise as a chemosensitization agent in BRCA-deficient EOC and merits clinical
investigation in this patient population.
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Background
Epithelial ovarian cancer (EOC) is the leading cause of
death among women with pelvic reproductive organ
cancer in the United States, with over 22,280 cases diag-
nosed and 15,500 deaths each year [1]. Despite the intro-
duction of new approaches to therapy, the high
mortality rate of EOC has remained largely static for
many years, with a 5-year overall survival rate of only
44.1 % in patients diagnosed between 2003 and 2009 [2].
Based on multiple phase III studies, the current standard
of care in the treatment of EOC is maximal surgical
cytoreduction followed by platinum-based chemother-
apy, most commonly carboplatin, in combination with
paclitaxel [3–5]. On the platinum-taxane regimen, up to
70-80 % percent of patients will enter remission [6].
However, despite this often excellent response to pri-
mary therapy, approximately 65 % of patients will ultim-
ately experience disease progression and require further
treatment [7]. At all stages of disease, progression-free
survival and overall survival depend greatly on the tumor
sensitivity to platinum chemotherapy. For patients who
become resistant to platinum therapy, response to other
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cytotoxic chemotherapeutic regimens is low, with re-
sponse rates of only 6-30 % [8].
Given the direct association between platinum resist-
ance and disease prognosis, the underlying mechanisms
resulting in platinum resistance are a focus of substan-
tial investigation. Various molecular mechanisms of
platinum resistance have been postulated, including
alterations in the AKT/mTOR and homologous recom-
bination (HR) repair pathways [9–11]. AKT, a serine/
threonine kinase family that is activated in a PI-3-K-
dependent manner, is involved in pathways regulating
cell growth and protein synthesis, entry into the cell
cycle, and cellular survival [12]. Activation of the AKT
pathway has been shown to promote a platinum-resistant
phenotype, whereas inhibition of AKT sensitizes chemore-
sistant cells to cisplatin-induced apoptosis [13]. Activation
of AKT also prevents cisplatin-induced phosphorylation
and activation of p53, required for the apoptotic response
to cisplatin treatment [14]. In addition, AKT2 is activated
above baseline in approximately 40 % of primary high-
grade ovarian cancers and transcriptionally amplified in a
further 12 % [15, 16]. Inhibition of AKT1 and AKT2 has
been demonstrated to selectively sensitize tumor cells to
apoptotic stimuli without commensurate effects on
normal cells [17]. MK-2206 is an orally active allosteric in-
hibitor of AKT that prevents AKT1 and AKT2 phosphor-
ylation at both the Thr308 and Ser473 sites, and also
prevents AKT-mediated phosphorylation of downstream
targets [18, 19]. It has been previously shown to
sensitize multiple human tumor cell lines to a variety of
anticancer agents [20], and is currently in phase II trials
as a single agent therapy for patients with recurrent
platinum-resistant ovarian, fallopian tube, and periton-
eal carcinoma (NCT01283035).
Other cellular responses to platinum-induced DNA
damage may also be involved in platinum resistance. HR
is a major mechanism for the repair of DNA double-
strand breaks (DSBs) [21]. Integral to this process are
the well-known tumor suppressor genes BRCA1 and
BRCA2. EOC with BRCA1 or BRCA2 mutations has
compromised HR activity and has long been known to
exhibit increased sensitivity to platinum drugs [22–25].
Additionally, the restoration of BRCA1/2 function in
initially BRCA1/2-deficient EOC has been linked to the
development of platinum resistance. The secondary res-
toration of BRCA1 function has been shown in a num-
ber of originally mutant EOC cell lines after resistance
had developed to cisplatin [26]. Defective HR repair also
renders BRCA-deficient cells susceptible to poly (ADP ri-
bose) polymerase (PARP) inhibitors, which compromise
base excision repair (BER), a complementary DNA repair
pathway [27]. Olaparib (AZD-2281, KU59436) is an oral
third-generation PARP-1 inhibitor that has demonstrated
substantial antitumor activity in BRCA-deficient EOC.
Notably, both pharmacological inhibition and siRNA-
knockdown of PARP-1 have been demonstrated to induce
activation of the anti-apoptotic AKT pathway and pro-
mote resistance to paclitaxel, raising concern for the need
for a specific AKT inhibitor to circumvent this drug-
induced drug resistance mechanism [28].
A number of studies have elucidated an intricate rela-
tionship between BRCA proteins and AKT activity.
BRCA1 has been implicated as a negative regulator of
AKT, targeting phosphorylated AKT for ubiquitination
and degradation in mammary tumors [29]. In addition,
the absence of BRCA2 has been implicated in increased
AKT signaling in prostate cancer, leading to increased
cell proliferation [30]. Conversely, AKT has also been
shown to antagonize the activity of BRCA1. In wild-
type sporadic breast cancer lines, AKT1 has been
shown to promote cytoplasmic retention of BRCA1
and Rad51. As both BRCA1 and Rad51 require nuclear
localization to participate in HR repair, this AKT1 ac-
tivity represses HR activity and creates a functional
phenotype similar to a BRCA1 mutant, commonly re-
ferred to as “BRCAness” [31, 32].
To date, no studies have elucidated the differential
effects of AKT inhibition on BRCA mutant versus wild-
type cell lines. Given the mutually antagonistic relation-
ship between AKT and BRCA1, and the repressive action
of AKT on HR repair, we hypothesized that BRCA mu-
tants might demonstrate higher levels of AKT activity
despite demonstrating increased susceptibility to DNA-
damaging agents. Additionally, the inhibition of AKT in
BRCA mutants might render cells more sensitive to
DNA-damaging agents, such as cisplatin. In this study,
we examined the effect of AKT inhibition with MK-2206
on the sensitivity of paired BRCA-proficient and –defi-
cient EOC cell lines to cisplatin and olaparib treatment.
Methods
Chemicals
Cisplatin was obtained from Calbiochem/EMD Millipore
(Billerica, MA, USA). Olaparib (AZD-2281), a selective
PARP1/PARP2 inhibitor, and MK-2206, a selective in-
hibitor of AKT1/AKT2/AKT3, were obtained from Sell-
eck Chemicals (Houston, TX, USA).
Experimental cell lines
The human ovarian adenocarcinoma cell lines PEO1 and
PEO4 were generously provided by Dr. Peter Glazer
(Yale University School of Medicine, New Haven, CT,
USA). PEO1 is a chemosensitive BRCA2-mutant poorly
differentiated serous ovarian adenocarcinoma derived
from malignant ascites of a patient with a BRCA2 germ-
line mutation 22 months after initial treatment with
cisplatin, 5-fluorouracil and chlorambucil. The patient
was subsequently retreated with platinum based therapy
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and had a further 10 month progression free interval,
indicating the platinum sensitivity of the disease at the
time of PEO1 retrieval. PEO4, a reverted BRCA2-
proficient line was derived from the same patient after
the development of chemotherapeutic resistance (the pa-
tient subsequently received high dose platinum therapy
with rapid progression) [33, 34]. Cells were maintained
in logarithmic growth in DMEM media with 10 % FBS
and penicillin/streptomycin antibiotics. To evaluate the
potential applicability of our findings to BRCA1 deficient
EOC, preliminary studies to determine AKT activity and
MK-2206 sensitivity were performed in the BRCA1 wild-
type human ovarian adenocarcinoma line SK-OV-3
(ATCC; Manassas, VA, USA). Non-targeted siRNA
control (NTC) and BRCA1-knockdown (BRCA1-kd) SK-
OV-3 cell lines were established in our lab as described
previously [35, 36]. Cells were maintained in logarithmic
growth in McCoy’s 5A media, supplemented with 10 %
fetal bovine serum (FBS) and penicillin-streptomycin an-
tibiotics. All cell lines used in this study are commer-
cially available and Human Investigation Committee
approval was not required.
Clonogenic assays
SK-OV-3 NTC and BRCA1-kd cells were seeded in
triplicate at various densities in 6-well plates. After
24 h of incubation, cells were treated continuously with
single drugs or combinations of cisplatin, olaparib, and
MK-2206. Plates were then incubated for 14 days, at
which point colonies were fixed and stained with crystal
violet/methanol (0.5 % crystal violet, 50 % methanol)
solution. All clonogenic assays used triplicate cultures
of each cell line, repeated three times. Colony counts
were obtained with an automated Bio-Rad GelDoc im-
aging system and QuantityOne analysis software (Bio-
Rad; Hercules, CA, USA).
Cytotoxic assays
PEO1 and PEO4 cells were seeded in 96-well plates at a
density of 5,000 cells/well. After 24 h of incubation, cells
were treated with single drugs or combinations of cisplatin,
olaparib, and MK-2206 in a fixed ratio of 1:1. After 72 h of
continuous incubation, wells were treated with CellTiter 96
AQueous One Solution Cell Proliferation Assay Reagent
(Promega; Madison, WI, USA). All cytotoxic assays used
triplicate cultures of each cell line, repeated three times.
Cells were incubated for 4 h before absorbances were read
at 490 nm with a colorimetric microplate reader. Data are
means ± standard deviation. Student T-tests were per-
formed to compare survival across cell lines.
Drug interaction analysis
To identify synergistic/antagonistic drug interactions,
Combination Indices (CI) were determined with CalcuSyn
software (Biosoft; Cambridge, UK) using the Chou-Talalay
method [37]. A CI > 1.00 indicates an antagonistic inter-
action between two drugs, and a CI < 1.00 indicates a
synergistic interaction. A CI near 1.00 represents near-
additive effects and minimal drug-drug interaction.
Western blot analysis
Cells were plated in 60-mm plates and incubated for
24 h prior to drug treatment, and then were incubated
for an additional 24 h with continuous drug exposure
until cells had reached 80 % confluence. For time course
experiments, the cells were incubated with continuous
drug exposure and lysed immediately following treat-
ment (Oh), and subsequently at 3, 6, 12, and 24 h. Cells
were lysed and protein concentrations were determined
by the Bio-Rad DC protein assay according to the manu-
facturer's instructions. Forty micrograms of protein were
resolved by electrophoresis in a 4–20 % polyacrylamide
Mini-PROTEAN TGX precast gel (BioRad) and trans-
ferred onto a nitrocellulose membrane. The membrane
was blocked with 5 % milk in TBST (Tris-buffered saline
with 0.05 % Tween-20) for 1 h at room temperature and
incubated with primary antibody in the blocking
solution at 4 °C overnight. The membrane was subse-
quently washed with TBST, incubated with a horseradish
peroxidase-conjugated secondary antibody in blocking
solution at room temperature for 1 h, and washed again.
The target protein was visualized by an enhanced chemi-
luminescence reagent (Denville Scientific; South Plainfield,
NJ, USA). Images were obtained with the Syngene
ChemDoc imaging system (Syngene; Frederick, MD,
USA). HSC-70 protein, a constitutively expressed member
of the 70-kDa heat shock protein family, was also used as a
secondary loading control in the event of uneven total AKT
expression via the procedure described above [38, 39].
Anti-phospho-AKT (Ser473; 193H12) (Thr308; 244 F9),
anti-AKT (40D4), anti-phospho-S6 ribosomal protein
(Ser235/236; 2 F9), anti-S6 ribosomal protein (54D2), and
anti-PARP antibodies were purchased from Cell Signaling
Technology (Beverly, MA, USA). Anti-HSC-70 (B-6) anti-
bodies were purchased from Santa Cruz Biotech (Dallas,
TX, USA). Individual western blotting analyses were per-
formed at least three times with separately prepared lysates
and a representative blot was chosen for display. Band
intensity was quantified with ImageJ software (National In-
stitute of Health, Bethesda, MD, USA).
Apoptosis assay
Cells were seeded in 6-well plates, and treated with drug
combinations of cisplatin or olaparib and MK-2206 after
24 h of incubation. After 72 h of continuous drug expos-
ure, cells were lysed (PBS, 1 % NP40, 0.1 % SDS). Cell
lysate (5 μl) was incubated with Caspase-Glo 3/7 Assay
reagent (Promega) at room temperature for 1 h and
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subsequently luminescence was measured with a TD-20/
20 luminometer (Turner Designs/Promega). Total pro-
tein concentration of cell lysates was determined as
described above. Caspase 3/7 activity was normalized to
total protein concentration and expressed as relative
luminescence units (RLU) per μg protein.
Results
BRCA mutant cell lines demonstrate higher levels of baseline
AKT activity
In both the SK-OV-3 and PEO paired cell lines, un-
treated cells showed similar baseline levels of total AKT.
However, both SK-OV-3 BRCA1-kd and PEO1, the
BRCA1-deficient and BRCA2 mutant cell lines, respect-
ively, showed higher levels of AKT phosphorylation at
the Ser473 site than in their BRCA-wild-type counter-
parts (Fig. 1). SK-OV-3 BRCA1-kd also showed higher
levels of AKT phosphorylation at Thr308. In all western
blotting experiments, PEO1 and PEO4 did not demon-
strate any detectable phosphorylation at the Thr308 site
and this is not shown going forward. Ribosomal S6 is a
downstream target of phospho-AKT (p-AKT) and its
phosphorylation status is useful as an indicator of activa-
tion of the AKT pathway [40]. The BRCA-deficient
PEO1 displayed higher levels of phosphorylated S6 than
the BRCA2-proficient PEO4.
BRCA mutant cell lines are more susceptible to cisplatin
and olaparib treatment
In cytotoxicity assays, both BRCA2-proficient PEO4 and
BRCA2-deficient PEO1 showed similar responses to
MK-2206, with PEO4 demonstrating marginally higher
susceptibility at all doses (Fig. 2a). The BRCA1-deficient
SK-OV-3 BRCA1-kd cells showed greater susceptibility
to MK-2206 at all doses as compared to BRCA1-
proficient SK-OV-3 NTC cells (Fig. 2b). BRCA2-proficient
PEO4 exhibited substantially decreased sensitivity to
cisplatin across the dose range as compared to BRCA2-
deficient PEO1 (Fig. 2a). Similarly, in clonogenic assays,
SK-OV-3 BRCA1-kd cells were markedly more sensitive
to cisplatin treatment than SK-OV-3 NTC cells (Fig. 2b).
Both BRCA-wild-type cell lines showed minimal re-
sponse to olaparib, with BRCA2-proficient PEO4 show-
ing almost 100 % survival at even the highest dose of
olaparib, while the BRCA mutants showed moderate
sensitivity at all doses.
Cisplatin and olaparib treatment induces AKT activation
in BRCA2 mutant cells
We then conducted western blot analysis to assess the
impact of single agent treatments on AKT phosphoryl-
ation and activity. As expected, treatment of all cell lines
with MK-2206 downregulated AKT and S6 phosphoryl-
ation in a dose-dependent manner in both PEO1 and
PEO4 (Fig. 3a). Downstream phosphorylation of S6 was
also decreased, although with a less precise dose–re-
sponse relationship. At 24 h, cisplatin treatment resulted
in lower levels of AKT and S6 phosphorylation than at
baseline in the PEO1 BRCA2-deficient cells (Fig. 3b).
AKT phosphorylation was largely unaltered by cisplatin
treatment in the PEO4 BRCA2-proficient cells at 24 h.
A similar dose-responsive decrease in p-S6 levels is
apparent in the BRCA2-deficient but not in the BRCA2-
proficient cells (Fig. 3b). However, when the experiment
was repeated with PEO1 and PEO4 cell lysates collected
at shorter post treatment time intervals, increased
phosphorylation of AKT is observed in both PEO1 and
PEO4 cells. Maximum activation of AKT is observed at
12 h post treatment, with subsequent depletion below
baseline by the 24 h time point. Olaparib treatment in-
duces AKT activation in the BRCA2 mutant PEO1. We
also detected mild induction of AKT phosphorylation
in the BRCA-proficient PEO4. S6 phosphorylation re-
flects the trend of AKT activation in the BRCA2 mutant
PEO1 (Fig. 3c).
MK-2206 sensitizes BRCA2 mutants to cisplatin and
olaparib therapy
In cytotoxicity assays, MK-2206 demonstrated strong,
dose-independent synergism with cisplatin treatment in
the PEO1 BRCA2-deficient cells (Fig. 4a, 1). In contrast,
MK-2206 antagonized the cytotoxic effects of cisplatin
in BRCA2-proficient PEO4 at all but the highest dose
(Fig. 4a, 2). In BRCA2-proficient PEO4 cells, the survival
curve of the cisplatin and MK-2206 combination closely
follows the survival curve of MK-2206 monotherapy.
Fig. 1 BRCA mutant cell lines demonstrate higher levels of baseline
AKT activity. PEO1, PEO4, and SK-OV-3 NTC and BRCA1-kd cells were
untreated and levels of phosphorylated and total AKT and S6 proteins
were assessed by western blot analysis
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Similarly, co-treatment with MK-2206 selectively induced
enhanced activation of caspase 3/7 in PEO1 cells treated
with all doses of cisplatin while only resulting in slight but
significant differential induction of apoptosis at the high-
est dose of cisplatin in PEO4 cells, likely in response to
the overwhelming DNA damage at the highest doses of
cisplatin (Fig. 4a, 3). The combination of olaparib and
MK-2206 also resulted in mild to moderate, dose inde-
pendent synergism in BRCA2-deficient PEO1 cells, while
resulting in very strong antagonism at all doses in the
BRCA2-proficient PEO4 line (Fig. 4b). Initial experiments
demonstrated that co-treatment with MK-2206 failed to
enhance caspase 3/7 activation in PEO1 cells treated with
olaparib. We hypothesized that this discrepancy reflected
that the chosen concentration of MK-2206 (1 μM) was
too low to enhance apoptosis induced by olaparib (Fig. 4b,
3a). Increased concentrations of MK-2206 in combination
with olaparib resulted in a clear dose responsive induction
of caspase 3/7 activity in the BRCA2-deficient PEO1 cells
while caspase 3/7 activity was unaffected in the BRCA2-
proficient PEO4 even at maximal doses of olaparib and
MK-2206 (Fig. 4b, 3b).
MK-2206 prevents cisplatin- and olaparib-induced AKT
phosphorylation
MK-2206 co-treatment repressed phosphorylation of
AKT and S6 in the BRCA2 mutant PEO1 treated with
cisplatin (Fig. 5a). AKT activity was reduced by MK-
2206 treatment to undetectable levels at all doses of cis-
platin despite robust levels of total AKT. p-S6 levels
were also markedly reduced. In BRCA2-proficient PEO4,
the low levels of p-AKT with cisplatin treatment were
also obliterated by MK-2206. A similar trend was ob-
served with the combination of olaparib and MK-2206
(Fig. 5b). MK-2206 inhibited the phosphorylation of
AKT in the BRCA2 mutant PEO1 at all doses of ola-
parib, while p-S6 levels were reduced but still evident. In
PEO4, the low level of p-AKT in olaparib-treated cells
was reduced to undetectable levels by MK-2206 treat-
ment. p-S6 levels were again reduced but still detectable.
MK-2206 sensitizes BRCA2 mutants to combination
therapy with cisplatin and olaparib
We conducted cytotoxicity assays to assess the effects of
cisplatin, olaparib, and MK-2206 in triple combination
Fig. 2 BRCA mutant cell lines are more susceptible to cisplatin and olaparib treatment. a Cytotoxicity Assay: PEO1 and PEO4 cells were treated with
various concentrations of MK-2206, cisplatin, and olaparib. After 72 h, MTS solution was added and absorbance read at 490 nm after 4 h. Data are means ±
SD. Survival is significantly different (p< 0.001) at all points with the exception of the 0.78 μM concentration of olaparib (p= 0.27). b Clonogenic Assay:
SK-OV-3 NTC and BRCA1-kd cells were exposed continuously to various concentrations of MK-2206, cisplatin, and olaparib. After 13 days, colonies were
stained and clonogenic survival was determined. Data are means ± SD
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on PEO1 and PEO4. Cells were treated with a fixed 1:1
ratio of cisplatin and olaparib dosing and three fixed
doses of MK-2206 (0, 3.125, and 6.25 μM). The combin-
ation of cisplatin and olaparib without MK-2206 showed
moderate synergism at lower doses but a trend of dimin-
ishing synergism toward higher doses in BRCA2-
deficient PEO1, while demonstrating antagonism at most
doses in BRCA2-proficient PEO4 (Fig. 6d). The addition
of MK-2206 showed mild to moderate synergism of the
triple combination at the higher doses in PEO1 and
moderate to strong antagonism at almost all tested doses
in PEO4.
Discussion
Chemotherapeutic sensitivity and resistance is a key fac-
tor in the treatment of EOC. AKT, which is involved in
Fig. 3 Effects of MK-2206, cisplatin, and olaparib on AKT activity in BRCA wild-type and mutant EOC cells. a PEO1 and PEO4 cells were treated with
0.3 μM, 1 μM, or 3 μM MK-2206 (MK) for 24 h. Band intensities quantified with ImageJ software. b 1. PEO1 and PEO4 cells were treated with 0.625 μM,
1.25 μM, or 2.5 μM cisplatin (Cis) for 24 h. 2. PEO1 and PEO4 cells were treated with 2.5 μM cisplatin (Cis) for 0, 3, 6, 12, and 24 h. c PEO1 and PEO4 cells
were treated with 0.625 μM, 1.25 μM, or 2.5 μM olaparib (AZD) for 24 h. Total proteins were assessed for the levels of phosphorylated and total AKT
and S6 by western blot analysis. HSC-70 protein levels were also used as a loading control. The ratios of phosphorylated protein to total protein relative
to that of the control of PEO1 (set as 1) are shown in bar graphs
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pro-survival and anti-apoptotic cell signaling pathways,
has been implicated in chemotherapeutic resistance
and has been identified as a potential target for
chemotherapeutic strategies. In addition, novel che-
motherapeutic strategies attempt to exploit the under-
lying weaknesses of the cancer cells themselves.
BRCA1 and BRCA2 mutations in EOC cell lines result
in compromised HR repair, the primary cellular mech-
anism for the repair of DSBs.
Here, we elucidate the relationship between BRCA1/2
deficiency and the AKT survival pathway, and propose a
targeted chemotherapeutic strategy for BRCA1/2 mutant
EOC. This study suggests that AKT activity is upregulated
in BRCA1 and BRCA2 mutant EOC, and that the inhib-
ition of AKT phosphorylation by the allosteric inhibitor
MK-2206 sensitizes BRCA mutants to apoptosis induced
by cisplatin and olaparib. Given the ability of AKT to
override apoptotic signaling, we propose that the baseline
increased AKT activity in BRCA mutant cells reflects not
only the lack of the repressive function of BRCA but also
enhancement of a primary survival mechanism in the
presence of faulty DNA repair. Therefore, removing a
fundamental compensatory mechanism renders BRCA
mutant cells exquisitely sensitive to additional DNA dam-
age caused by platinum drugs and PARP inhibitors.
First, western blot analysis suggests higher levels of
AKT activation in both BRCA1 and BRCA2 mutant cell
lines at baseline prior to any drug treatment. Both
SKOV3 BRCA1-kd and BRCA2 mutant PEO1 showed
substantial phosphorylation at the Ser473 site and
SKOV3 BRCA1-kd also showed a low level of increased
phosphorylation at the Thr308 site. As mentioned previ-
ously, our experiments did not demonstrate AKT phos-
phorylation at the Thr308 site in any of the PEO1/4
cells. Whether this discrepancy reflects a true difference
in the activation of the two phosphorylation sites is un-
clear. While the differential effects of phosphorylation at
the two sites has not been fully characterized and are a
subject of ongoing investigation, defects in Ser473 phos-
phorylation have been shown to affect only a subset of
the total targets of AKT function. For example, S6-
kinase phosphorylation (the kinase that when activated
phosphorylates S6), notably, was not affected in vivo by
lack of Ser473 phosphorylation, and AKT that is phos-
phorylated at only the Thr308 site showed continued
partial activity [41]. Investigation into the exact mecha-
nisms of AKT to S6 signaling is ongoing. Treatment
with increasing doses of MK-2206 resulted in a clear
dose-responsive downregulation of AKT phosphoryl-
ation in both BRCA-proficient and deficient cells.
Although we observed a corresponding downregulation
of S6 phosphorylation, there is not the same dose
response. The inexact correlation between AKT phos-
phorylation and S6 phosphorylation may be attributable
to the independence of S6 from the Ser473 site dis-
cussed previously. However, treatment with olaparib
appears to induce phosphorylation of both AKT and S6
in BRCA2 mutant cells while still showing no activation
at the Thr308 site. The fact that S6 is activated in
(See figure on previous page.)
Fig. 4 MK-2206 sensitizes BRCA2 mutants to cisplatin and olaparib therapy. a 1. PEO1 and PEO4 cells were treated with various concentrations of
cisplatin, MK-2206, or both in combination at a constant 1:1 ratio. After 72 h, MTS solution was added and absorbance read at 490 nm after 4 h. Data
are means ± SD. 2. CI values were calculated for the drug combination of cisplatin and MK-2206 at each concentration. 3. PEO1 and PEO4 cells were
treated with increasing doses of cisplatin in combination with 1 μM MK-2206 and caspase 3/7 activity determined after 72 h. b 1. Assay repeated for
the combination of olaparib and MK-2206. 2. CI values for olaparib and MK-2206 3. a. Caspase 3/7 activity assay for olaparib and MK-2206 (1 μM) .
Asterisks, p < 0.05 (Student’s t-test) b Caspase 3/7 activity assay for olaparib and MK-2206 (1, 3, and 6 μM)
Fig. 5 MK-2206 prevents cisplatin- and olaparib-induced AKT
phosphorylation. a PEO1 and PEO4 cells were treated with 1 μM
MK-2206 in combination with 0.625 μM, 1.25 μM, or 2.5 μM
cisplatin for 24 h. Levels of phosphorylated and total AKT and
S6, and HSC-70 proteins were assessed by western blot analysis.
b PEO1 and PEO4 cells were treated with 1 μM MK-2206 in
combination with 0.625 μM, 1.25 μM, or 2.5 μM olaparib for 24 h.
Levels of phosphorylated and total AKT and S6, and HSC-70
proteins were assessed by western blot analysis
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sequence with Ser473 suggests that their function is ei-
ther more closely linked than was previously indicated,
or that this western blot assay does not accurately reflect
levels of Thr308 phosphorylation.
In contrast to olaparib treatment in PEO1 cells, initial
studies with treatment with cisplatin resulted in de-
creased levels of phosphorylated AKT at 24 h. However,
previous work in HCT-116 human colon carcinoma cells
revealed maximum induction of AKT phosphorylation
at 6 h post treatment with cisplatin. At 24 h post treat-
ment, p-AKT levels were found to be below baseline
after the initial intense activation of AKT in response to
the devastating DNA damage resulting from cisplatin
treatment [42]. In this context, we hypothesized that the
apparent downregulation of AKT activation in response
to cisplatin activation in fact represented depletion of p-
AKT after maximum activation earlier in the time
course. Subsequent experiments revealed maximum
levels of p-AKT at 12 h with subsequent depletion by
the 24 h mark in both PEO1 and PE04 cell lines. The
apparent inverse dose response of AKT activation at
24 h with increasing dose of cisplatin may therefore rep-
resent increased depletion of p-AKT after a progressively
more intense, dose-proportionate response to greater
DNA insult. The uniformity of the phosphorylation level of
AKT in PEO4 across all doses of cisplatin at 24 h,may be
reflective of the cisplatin resistance inherent in the BRCA-
proficient line. As PEO4 has intact HR repair and is better
equipped to manage platinum–induced DNA damage, it is
less reliant on AKT activation for apoptotic override, and
the dose response relationship is not as precise.
Consistent with published data, both of the BRCA-
deficient cell lines demonstrated better apoptotic re-
sponse to cisplatin and olaparib. As we have established
that the BRCA2 mutant cells have higher AKT activity at
baseline and then further increase AKT activity in re-
sponse to DNA damage, it is unlikely, despite the known
connection between AKT activation and platinum resist-
ance in other models, that the difference in platinum
resistance between the BRCA-proficient and -deficient
cells is fully mediated by increased AKT activation in the
BRCA-proficient cells. The increased sensitivity to ola-
parib is consistent with the literature and attributable to
the synthetic lethality of PARP inhibition in the setting
of defective HR repair in BRCA2-deficient cells [43, 44].
The combination of cisplatin with MK-2206 in the
BRCA2 mutant showed moderate synergism at all doses.
As cisplatin treatment alone appears to upregulate AKT
phosphorylation in the BRCA mutant line, it is likely
that AKT activation is a key mechanism for survival in
the face of platinum-induced DNA damage. When this
mechanism is impeded, the BRCA-deficient cells are un-
able to mount a response against the cisplatin-induced
apoptosis. In contrast, AKT inhibition with MK-2206
antagonizes the action of cisplatin in PEO4. It is unlikely
that the cisplatin resistance in PEO4 is completely attrib-
utable to upregulated AKT activity, and so the inhibition
of AKT has little impact on the cytotoxic effects of
cisplatin. The strong synergism seen at the highest dose
of the cisplatin and MK-2206 in combination in PEO4 is
likely mathematically attributable to the high overall kill
rate at the highest drug doses.
MK-2206 exhibited mild to moderate synergism with
olaparib in the BRCA2 mutant at most doses. The com-
bination of olaparib and MK-2206 in the BRCA2 mutant
is unique in that it may create two separate mechanisms
of synthetic lethality. As described above, the BRCA mu-
tant may be reliant on AKT activity at baseline, and thus
is particularly susceptible to AKT inhibition. Olaparib,
as a PARP inhibitor, compromises NER and compounds
the BRCA2 mutant’s underlying defect in HR repair. In
contrast, as the BRCA2-proficient PEO4 cell line was
predictably unresponsive to olaparib at all doses, the
overall survival of the cells exposed to the combination
is essentially the same as treating them with MK-2206
alone. The less dramatic response of the BRCA mutant
cells to the olaparib and MK-2206 combination as op-
posed to cisplatin and MK-2206 may be attributable to
less intrusive DNA damage and cytotoxicity caused by
the tested dose range of olaparib, which requires HR for
repair, as compared to cisplatin, which requires both HR
and NER. In BRCA mutant cells, olaparib induces the
accumulation of DSBs, as existing single-strand breaks
stall the replication fork and are converted to DSBs in
the absence of functional PARP [45]. In contrast, the
DNA adducts formed by cisplatin cross-links induce the
formation of both double- and single-strand breaks and
activate a broad range of proapoptotic pathways includ-
ing ATR, p53, p73, and MAPK [46].
While olaparib and MK-2206 each have some individ-
ual cytotoxic effect, they are likely to be most effective
in triple combination with cisplatin or another DNA-
damaging agent. Our studies of the triple combination
demonstrate mild to moderate synergism of the triple
combination of cisplatin, olaparib, and MK-2206 in the
BRCA2-deficient PEO1. In contrast, the triple combin-
ation showed strong antagonism at almost all tested
doses in BRCA2-proficient PEO4. It is important to
(See figure on previous page.)
Fig. 6 MK-2206 sensitizes BRCA2 mutants to combination therapy with cisplatin and olaparib. PEO1 and PEO4 cells were treated with (a) 0, (b) 3.125, or (c)
6.25 μM MK-2206 in combination with a fixed ratio (1:1) of cisplatin and olaparib. After 72 h, MTS solution was added and absorbance read at 490 nm after
4 h. Data are means ± SD. d CI values were calculated for the drug combinations of cisplatin and olaparib with MK-2206 at each concentration
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note, however, that the combination of cisplatin and ola-
parib alone, without MK-2206, showed synergism at
lower doses, and there did not appear to be a dramatic
increase in synergism with the addition of MK-2206.
Here we may face the limitations of the Chou-Talalay
method. Due to limitations in the practicality of multiple
drug dosing in the 96-well plates for cytotoxic assay,
cisplatin and olaparib were dosed in a 1:1 fixed ratio,
while MK-2206 was added in two fixed levels. We specu-
late that the mathematics of the Chou-Talalay method
favor fixed ratio drug combinations [47], and therefore
may be less sensitive to added synergism due to MK-
2206 in this experiment. Additionally, treating cells in a
continuous manner for 72 h with cisplatin and olaparib
rather than conducting washout of the drug after a short
interval may induce DNA damage too profound to be
dramatically affected by further inhibition of AKT. Fur-
ther examination with alternative experimental design is
necessary for additional confirmation of synergistic phe-
nomena with the triple drug combination treatment.
A limitation of this study is the use of monolayer cell
culture as our primary experimental modality, given the
discrepancy between condition in monolayer cell cul-
tures and the in-vivo environment they are intended to
model. To this end, further work in both spheroid cell
models and in-vivo mouse models is currently ongoing
in our laboratory.
Conclusion
In summary, by targeting the baseline reliance of the BRCA
mutant cells on AKT activity for survival, we created a syn-
thetic lethal combination with MK-2206. The BRCA mu-
tant, having already exhausted a potent survival mechanism
in the face of compromised HR repair, is unable to with-
stand the DNA damage from cisplatin or olaparib. AKT
inhibition by MK-2206 produces a unique synthetic lethal-
ity and will potentially sensitize BRCA mutants to DNA-
damaging and PARP -inhibitor therapy for ovarian cancer.
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